PDF(Sci-hub)
Abstract：
Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
摘要：
最近的随机试验表明，一线ipilimumab和nivolumab联合治疗具有生存益处。以及派姆单抗和阿西替尼联合治疗转移性透明细胞肾细胞癌。欧洲泌尿外科协会指南小组根据这些研究更新了其建议。患者总结：Pembrolizumab+axitinib是一种新的治疗标准，适用于诊断为肾癌扩散到肾外且未接受任何癌症治疗（未接受治疗）的患者。这适用于国际转移性肾细胞癌数据库联盟标准确定的所有风险组。
